Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Subscribe To Our Newsletter & Stay Updated